← All trials
NCT00704665
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 1998
- Primary completion
- Dec 1, 2001
- Completion date
- Dec 1, 2001
- First posted
- —
- Last posted
- —
- Enrollment
- 231
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of Medicine and Dentistry of New JerseyLead sponsor
- University of California, Los AngelesCollaborator
- Boston UniversityCollaborator
- University of ChicagoCollaborator
- Johns Hopkins UniversityCollaborator
- University of PittsburghCollaborator
- Stanford UniversityCollaborator
- Georgetown UniversityCollaborator
- University of California, San DiegoCollaborator
- Wayne State UniversityCollaborator
- University of Colorado, DenverCollaborator
- Medical College of WisconsinCollaborator
- Medical University of South CarolinaCollaborator
- University of ConnecticutCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.